Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di ricerca che confronta l'efficacia di diverse dosi del medicinale NN0519-0130 nel ridurre lo zucchero nel sangue nelle persone con diabete di tipo 2

18 settembre 2026 aggiornato da: Novo Nordisk A/S

Indagine sulla sicurezza e sull'efficacia di NNC0519-0130 una volta alla settimana nei partecipanti con diabete di tipo 2: uno studio per l'individuazione della dose

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

299

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Campbelltown, New South Wales, Australia, 2560
        • Campbelltown Hospital
      • Macquarie Park, New South Wales, Australia, 2109
        • Macquarie University - Clinical Trials Unit
      • St Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital
      • Sydney, New South Wales, Australia, 2148
        • Western Endocrine Blacktown
      • Sydney, New South Wales, Australia, 2148
        • Roger Chih Yu Chen
      • Wollongong, New South Wales, Australia, 2500
        • Illawarra Diabetes Service Clinical Trials & Research Unit
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • University of Sunshine Coast - Vitality Village
      • Meadowbrook, Queensland, Australia, 4131
        • Logan Hospital
    • South Australia
      • Oaklands Park, South Australia, Australia, 5046
        • Southern Adelaide Diabetes & Endocrine Services
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Eastern Clinical Research Unit Box Hill
      • Camberwell, Victoria, Australia, 3124
        • Emeritus Research Melbourne
      • Heidelberg Heights, Victoria, Australia, 3081
        • Austin Health, Metabolic Disorders Centre
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital - Diabetes & Endocrinology Department
    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Fremantle Hospital
      • Québec, Canada, G1V 4T3
        • Diex Recherche Quebec
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Richmond, British Columbia, Canada, V6V 2L1
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Victoria, British Columbia, Canada, V8V 4A1
        • Cook Street Medical Clinic
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1G 1A7
        • G.A. Research Associates Ltd.
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 1V7
        • Nova Scotia Hlth Halifax
    • Ontario
      • Barrie, Ontario, Canada, L4N 7L3
        • Centricity Research Barrie
      • Hamilton, Ontario, Canada, L8L 5G8
        • Wharton Medical Clinic Clinical Trials (Hamilton)
      • Sarnia, Ontario, Canada, N7T 4X3
        • London Road Diagnostic Clinic and Medical Centre
      • Toronto, Ontario, Canada, M4G 3E8
        • Centricity Research Toronto
      • Toronto, Ontario, Canada, M9V 4B4
        • Albion Finch Medical Centre
    • Quebec
      • Lévis, Quebec, Canada, G6W 0M5
        • Centricity Research Quebec City
      • Mirabel, Quebec, Canada, J7J 2K8
        • Centricity Research Mirabel
      • Montreal, Quebec, Canada, H1Y 3H5
        • Recherche GCP Research
      • Saint-Laurent, Quebec, Canada, H4T 1Z9
        • Centricity Research Ville St. Laurent VSL
      • Seoul, Corea del Sud, 05505
        • Asan Medical Center
      • Seoul, Corea del Sud, 01830
        • Nowon Eulji Medical Center, Eulji University
      • Seoul, Corea del Sud, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Corea del Sud, 02841
        • Korea University Anam Hospital
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
        • Seoul National University Bundang Hospital
      • Chiba, Giappone, 261-0004
        • Tokuyama clinic_Diabetic internal medicine
      • Soka-shi, Saitama, Giappone, 340-0015
        • Soka Sugiura Internal Medicine Clinic
      • Tokyo, Giappone, 104-0031
        • Fukuwa Clinic
      • Tokyo, Giappone, 103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo, Giappone, 104-0031
        • Fukuwa Clinic_Internal Medicine
      • Bengaluru, India, 560054
        • MS Ramaiah
      • New Delhi, India, 110001
        • Lady Hardinge Medical College
    • Karnataka
      • Bangalore, Karnataka, India, 560092
        • Life Care Hospital and Research Centre
    • Kerala
      • Kochi, Kerala, India, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Madhya Pradesh
      • Indore, Madhya Pradesh, India, 452010
        • TOTALL Diabetes Hormone Institute
    • Maharashtra
      • Mumbai, Maharashtra, India, 400012
        • Seth GS Medical College & KEM Hospital
      • Pune, Maharashtra, India, 411021
        • Chellaram Diabetes Institute
    • Rajasthan
      • Jaipur, Rajasthan, India, 302006
        • Diabetes, Thyroid and Endocrine Centre
    • Tamil Nadu
      • Vellore, Tamil Nadu, India, 632004
        • Christian Medical College Hospital, Vellore
    • Telangana
      • Hyderabad, Telangana, India, 500082
        • Diabetes Research Center, Hyderabad
    • California
      • Chula Vista, California, Stati Uniti, 91911
        • Velocity Clin Res-Chula Vista
      • Fresno, California, Stati Uniti, 93720
        • Valley Research
      • Inglewood, California, Stati Uniti, 90301
        • 310 Clinical Research
      • La Mesa, California, Stati Uniti, 91942
        • Velocity Clin Res San Diego
      • Lancaster, California, Stati Uniti, 93534
        • First Valley Med Grp Lancaster
      • Lomita, California, Stati Uniti, 90717
        • Torrance Clin Res Inst, Inc.
      • Los Alamitos, California, Stati Uniti, 90720
        • Pacific Clinical Studies
      • Los Angeles, California, Stati Uniti, 90057
        • Velocity Clinical Research Westlake
      • Montclair, California, Stati Uniti, 91763
        • Catalina Research Institute, LLC
      • San Diego, California, Stati Uniti, 92123
        • Artemis Insitute for Clin Res
      • Toluca Lake, California, Stati Uniti, 91602
        • Med Partners, Inc.
      • Torrance, California, Stati Uniti, 90505
        • UCLA Health Southbay Endocrine
      • Tustin, California, Stati Uniti, 92780
        • University Clin Investigators
      • Walnut Creek, California, Stati Uniti, 94598
        • Diablo Clinical Research, Inc.
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado Hospital
    • Florida
      • Clearwater, Florida, Stati Uniti, 33756
        • Innovative Research of W Florida Inc.
      • Clearwater, Florida, Stati Uniti, 33756
        • Innovative Research of W FL
      • Miami, Florida, Stati Uniti, 33183
        • International Research Associates, LLC_Miami
    • Georgia
      • Columbus, Georgia, Stati Uniti, 31904
        • Centricity Research
    • Idaho
      • Blackfoot, Idaho, Stati Uniti, 83221
        • Elite Clinical Trials
    • Illinois
      • Peoria, Illinois, Stati Uniti, 61603
        • Methodist Medical Center of Illinois
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa
    • Maryland
      • Columbia, Maryland, Stati Uniti, 21045
        • Centennial Medical Group
      • Oxon Hill, Maryland, Stati Uniti, 20745
        • MD Medical Research
      • Rockville, Maryland, Stati Uniti, 20852
        • Endo And Metab Cons
    • Missouri
      • Springfield, Missouri, Stati Uniti, 65807
        • Clinvest Research
    • Montana
      • Butte, Montana, Stati Uniti, 59701
        • Mercury Str Med Grp, PLLC
    • Nebraska
      • Lincoln, Nebraska, Stati Uniti, 68510
        • Velocity Clinical Research Lincoln
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89148
        • Palm Research Center Inc-Vegas
      • Las Vegas, Nevada, Stati Uniti, 89109
        • Excel Clinical Network
    • New York
      • Binghamton, New York, Stati Uniti, 13905
        • Velocity Clinical Research Binghamton
    • North Carolina
      • Greensboro, North Carolina, Stati Uniti, 27408
        • PharmQuest Life Sciences LLC
      • Wilmington, North Carolina, Stati Uniti, 28401
        • Accellacare Wilmington
    • Ohio
      • Canton, Ohio, Stati Uniti, 44718
        • Diab & Endo Assoc of Stark Co
      • Cincinnati, Ohio, Stati Uniti, 45242
        • Velocity Clin Res_Cincinnati
      • Cincinnati, Ohio, Stati Uniti, 45246
        • Velocity Clinical Research Springdale
      • Dayton, Ohio, Stati Uniti, 45439
        • Providence Health Partners Ctr
      • Maumee, Ohio, Stati Uniti, 43537
        • Advanced Med Res Maumee
    • Oregon
      • Grants Pass, Oregon, Stati Uniti, 97527
        • Velocity Clin Res Grants Pass
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19114
        • Tristar Clin Investigations, PC
      • Pittsburgh, Pennsylvania, Stati Uniti, 15243
        • Preferred Primary Care Physicians Inc.
      • Uniontown, Pennsylvania, Stati Uniti, 15401
        • Preferred Primary Care Physicians, Inc.
    • Texas
      • Abilene, Texas, Stati Uniti, 79606
        • Velocity Clinical Research Abilene
      • Austin, Texas, Stati Uniti, 78759
        • Velocity Clin Res Austin
      • Dallas, Texas, Stati Uniti, 75390
        • UT Southwestern Med Center
      • Dallas, Texas, Stati Uniti, 75230
        • Velocity Clinical Res-Dallas
      • Dallas, Texas, Stati Uniti, 75230
        • Zenos Clinical research
      • Forney, Texas, Stati Uniti, 75126
        • Care United Research, LLC
      • Houston, Texas, Stati Uniti, 77004
        • Endocrine Associates Houston
      • Houston, Texas, Stati Uniti, 77043
        • Biopharma Informatic_Houston
      • Irving, Texas, Stati Uniti, 75039
        • Tekton Research
      • Lewisville, Texas, Stati Uniti, 75057
        • Epic Clinical Research
      • Shavano Park, Texas, Stati Uniti, 78231
        • Consano Clinical Research, LLC
    • Virginia
      • Burke, Virginia, Stati Uniti, 22015
        • Burke Internal Medicine & Research
      • Newport News, Virginia, Stati Uniti, 23606
        • TPMG Clinical Research
    • Free State
      • Bloemfontein, Free State, Sud Africa, 9301
        • Josha Research
    • Gauteng
      • Johannesburg, Gauteng, Sud Africa, 2013
        • Wits Bara Clinical Trial Site
      • Midrand, Gauteng, Sud Africa, 1685
        • Dr A Jacovides and Partners Inc
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Sud Africa, 4450
        • Dr Pillay's Rooms
      • eMkhomazi, KwaZulu-Natal, Sud Africa, 4170
        • Dr T Padayachee

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Female of non-childbearing potential, or male.
  • For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
  • Age 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
  • Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
  • Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dosing scheme A (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Comparatore placebo: Dosing scheme A (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Sperimentale: Dosing scheme B (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Comparatore placebo: Dosing scheme B (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Sperimentale: Dosing scheme C (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Comparatore placebo: Dosing scheme C (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Sperimentale: Dosing scheme D (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Comparatore placebo: Dosing scheme D (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Sperimentale: Dosing scheme E (NNC0519-0130)

Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Comparatore placebo: Dosing scheme E (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Comparatore attivo: Dosing scheme F (tirzepatide)

Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.

Trizepatide will be administered subcutaneously.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Glycated haemoglobin (HbA1c)
Lasso di tempo: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as percentage point (%-point)

From baseline (week 0) to 12 weeks on a given maintenance dose

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Glycated haemoglobin (HbA1c)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as percentage point (%-point)

From baseline (week 0) to end of treatment (week 36)
Relative change in body weight
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as percentage (%)

From baseline (week 0) to end of treatment (week 36)
Change in body weight
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as kilograms (kg)

From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
Lasso di tempo: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as millimoles per liter (mmol/L)

From baseline (week 0) to 12 weeks on a given maintenance dose
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Lasso di tempo: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively

Measured as percentage point (%-point)

From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
Change in waist circumference
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as centimeter (cm)

From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as millimeters of mercury (mmHg)

From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Number of adverse events
Lasso di tempo: From baseline (week 0) to end of study (week 40)

Measured as number of events

From baseline (week 0) to end of study (week 40)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 marzo 2024

Completamento primario (Effettivo)

19 settembre 2025

Completamento dello studio (Effettivo)

13 ottobre 2025

Date di iscrizione allo studio

Primo inviato

16 marzo 2024

Primo inviato che soddisfa i criteri di controllo qualità

16 marzo 2024

Primo Inserito (Effettivo)

22 marzo 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NN9541-4945
  • U1111-1291-9196 (Altro identificatore: World Health Organization (WHO))
  • jRCT2031230704 (Identificatore di registro: JRCT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi